Keros Therapeutics, Inc. (NASDAQ:KROS) Receives $42.33 Consensus Target Price from Analysts

Keros Therapeutics, Inc. (NASDAQ:KROS) has earned a consensus rating of “Moderate Buy” from the fourteen ratings firms that are covering the firm, MarketBeat.com reports. Six analysts have rated the stock with a hold recommendation and eight have given a buy recommendation to the company. The average 1-year price objective among analysts that have covered the stock in the last year is $42.33.

Several analysts have recently weighed in on the stock. TD Cowen cut shares of Keros Therapeutics from a “buy” rating to a “hold” rating in a research note on Thursday, December 12th. Piper Sandler lowered their price objective on Keros Therapeutics from $40.00 to $15.00 and set an “overweight” rating for the company in a research report on Friday, January 17th. Oppenheimer reduced their target price on Keros Therapeutics from $63.00 to $23.00 and set an “outperform” rating on the stock in a research report on Thursday, January 16th. Truist Financial lowered their price target on Keros Therapeutics from $100.00 to $43.00 and set a “buy” rating for the company in a report on Monday, December 23rd. Finally, William Blair lowered shares of Keros Therapeutics from an “outperform” rating to a “market perform” rating in a report on Thursday, December 12th.

Keros Therapeutics Stock Performance

NASDAQ KROS opened at $11.38 on Monday. The stock’s fifty day moving average is $12.00 and its two-hundred day moving average is $38.26. The firm has a market capitalization of $461.60 million, a P/E ratio of -2.18 and a beta of 1.39. Keros Therapeutics has a fifty-two week low of $9.77 and a fifty-two week high of $72.37.

Keros Therapeutics (NASDAQ:KROS) last announced its quarterly earnings results on Wednesday, February 26th. The company reported ($1.14) earnings per share for the quarter, beating the consensus estimate of ($1.36) by $0.22. Keros Therapeutics had a negative net margin of 27,890.94% and a negative return on equity of 41.74%. The firm had revenue of $3.04 million for the quarter, compared to analysts’ expectations of $37.32 million. As a group, sell-side analysts forecast that Keros Therapeutics will post -4.74 EPS for the current year.

Institutional Trading of Keros Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of KROS. AlphaQuest LLC boosted its position in Keros Therapeutics by 469.0% in the 4th quarter. AlphaQuest LLC now owns 3,596 shares of the company’s stock valued at $57,000 after buying an additional 2,964 shares during the period. Virtus ETF Advisers LLC raised its stake in shares of Keros Therapeutics by 107.5% in the fourth quarter. Virtus ETF Advisers LLC now owns 3,857 shares of the company’s stock valued at $61,000 after acquiring an additional 1,998 shares in the last quarter. KBC Group NV boosted its holdings in Keros Therapeutics by 52.0% in the third quarter. KBC Group NV now owns 1,263 shares of the company’s stock valued at $73,000 after purchasing an additional 432 shares during the period. Mirae Asset Global Investments Co. Ltd. grew its stake in Keros Therapeutics by 26.0% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,357 shares of the company’s stock worth $77,000 after purchasing an additional 280 shares in the last quarter. Finally, KLP Kapitalforvaltning AS acquired a new position in Keros Therapeutics during the 4th quarter worth $90,000. 71.56% of the stock is currently owned by hedge funds and other institutional investors.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.